Shares of Epizyme Inc (NASDAQ:EPZM) catapulted to a 65% gain early Tuesday in the wake of the company’s announcement that it achieved a proof-of-concept milestone for a therapy designed to treat genetically defined cancers. Epizyme Inc (NASDAQ:EPZM) stock opened at $34.31 in last trading session, and closed at $35.99, trading in the range of $31.02 – $37.69. The stock showed a positive weekly performance of 74.62%.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock has an average rating of Buy with an average Target Price of $4.00. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares closed at $5.30 on last trade day, by gaining 5.16%. Stock 52 week range is $0.19 – $5.55. Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s market capitalization is $247.65 billion.
One stock that might be an intriguing choice for investors right now is Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). This is because this security in the Biotechnology space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock surged 7.68% and finished the last session at $5.89. The EPS of the stock remained -0.64. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)’s market capitalization is $358.26 billion.
Array Biopharma Inc (NASDAQ:ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco. The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Array Biopharma Inc (NASDAQ:ARRY) stock opened at $4.93 in last trading session and closed at $5.16. Array Biopharma Inc (NASDAQ:ARRY)’s 52 week range of the stock is $3.66 – $7.10 and the day range was $4.89 -$ 5.25.